Engineers at the Massachusetts Institute of Technology have developed a new type of customizable vaccines using messenger RNA that has proven to effectively combat a wide range of lethal pathogens when administered to mice, and might be able to reduce disease outbreak response time in the future.
An international team of researchers has identified a potential role for certain monoclonal antibodies in developing a treatment for Zika virus.
Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) and the National Human Genome Research Institute (NHGRI) believe they have found the key to developing a universal vaccine for influenza.
The Hawaii State Department has confirmed an open investigation of the hepatitis A infection in Oahu, Hawaii.
The number of confirmed cases in the outbreak has been attributed to the reluctance of some to be vaccinated.
US travelers concerned about contracting cholera during overseas journeys to areas where the disease remains a threat may now have options as they seek to reduce their risk.
A recent review focuses on the biology of human papillomaviruses, their associated burdens, and the clinical data available on HPV vaccine efficacy.
A recent review article on the status of vaccines in development for healthcare associated infections (HAIs) provides both an in-depth discussion of their urgent need, as well as their potential for success.
Management of visceral leishmaniasis poses a daunting challenge, in part due to the side effects associated with the use of the traditional treatment. However, one vaccine development strategy has recently shown promising results.
The number of expecting mothers who opt for annual vaccination for influenza during pregnancy remains relatively low; however, the results of a new study suggest this may be changing—and that there are obvious benefits for immunization for newborns.
Rohit Bhalla, DO, Chief of the Section of Infectious Diseases at the University Medical Center of Princeton, discusses if we will see more vaccine-preventable diseases in the United States in the future.
Rohit Bhalla, DO, Chief of the Section of Infectious Diseases at the University Medical Center of Princeton, shares how healthcare practitioners can help stop the spread of mumps.
Dr. Rohit Bhalla, DO, Chief of the Section of Infectious Diseases at the University Medical Center of Princeton, explains why an individual could still become infected with mumps, even after receiving vaccinations.
A recent review article on the status of influenza vaccines, their short-comings, and ways to improve them suggests the potential for significant improvements in the performance of future influenza vaccines.
The on-again, off-again debut of the controversial film “Vaxxed: From Cover-up to Catastrophe” at the Tribeca Film Festival in March once again made the debate surrounding pediatric vaccination headline news.
Seasonal influenza results in nearly 50,000 deaths each year in the United States alone, and 5 to 10 times as many deaths in all industrialized countries combined.
Two investigational vaccines showed promise to protect against Ebola virus disease, according to data from the phase 2 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL 1) trial.
A recent study demonstrates the first evidence of the national impact of the HPV vaccine among females in their 20s.
Recent outbreaks of mumps in 14 US cities have prompted health alerts from local officials.
Researchers from the Dana-Farber Cancer Institute in Boston, MA have, for the first time, identified a link between a person's genetic make-up, as well as their ethnic background, and their response to influenza vaccine.
Many vaccine-preventable diseases persist and have increased in prevalence because of lowered immunity in the general population.
Reports of measles cases in a suburban Illinois infant care center have added to concerns the preventable but highly contagious illness is spreading.
The US Department of Health and Human Services (HHS) plans to spend $2.7 billion in emergency funds to counter the spread of Ebola. Spending categories range from over a half billion dollars for international projects to a half million dollars for regulatory work that includes monitoring for fraudulent Ebola products.
